ES2059356T3 - Inhibidor de la tripsina pancreatico secretor, preparado mediante tecnologia genetica y sus variantes. - Google Patents

Inhibidor de la tripsina pancreatico secretor, preparado mediante tecnologia genetica y sus variantes.

Info

Publication number
ES2059356T3
ES2059356T3 ES87119221T ES87119221T ES2059356T3 ES 2059356 T3 ES2059356 T3 ES 2059356T3 ES 87119221 T ES87119221 T ES 87119221T ES 87119221 T ES87119221 T ES 87119221T ES 2059356 T3 ES2059356 T3 ES 2059356T3
Authority
ES
Spain
Prior art keywords
secretor
variants
prepared
trypsin inhibitor
pancreatic trypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87119221T
Other languages
English (en)
Inventor
John Prof Dr Collins
Helmut Dr Blocker
Ronald Dr Frank
Friedhelm Dr Maywald
Hans Prof Dr Fritz
Wolfgang Dr Bruns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2059356T3 publication Critical patent/ES2059356T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL PRESENTE INVENTO CONSISTE EN UN PEPTIDO QUE MUESTRA EN LO ESENCIAL LA SECUENCIA DE AMINOACIDOS DEL INHIBIDOR DE TRIPSINA (PSTI) SECRETOR PANCREATICO. EL INVENTO CONSISTE EN VARIANTES DE ESTE PEPTIDO, EN QUE SE REEMPLAZA UNO O VARIOS DE LOS AMINOACIDOS DE LA SECUENCIA ORIGINAL POR OTROS AMINOACIDOS. ADEMAS SE DESCRIBE UN PROCEDIMIENTO PARA FABRICACION DEL PEPTIDO ASI COMO SU UTILIZACION FARMACEUTICA.
ES87119221T 1987-01-07 1987-12-24 Inhibidor de la tripsina pancreatico secretor, preparado mediante tecnologia genetica y sus variantes. Expired - Lifetime ES2059356T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08700204A GB2199582A (en) 1987-01-07 1987-01-07 Analogues of pancreatic secretory trypsin inhibitor

Publications (1)

Publication Number Publication Date
ES2059356T3 true ES2059356T3 (es) 1994-11-16

Family

ID=10610323

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87119221T Expired - Lifetime ES2059356T3 (es) 1987-01-07 1987-12-24 Inhibidor de la tripsina pancreatico secretor, preparado mediante tecnologia genetica y sus variantes.

Country Status (15)

Country Link
US (1) US5126322A (es)
EP (1) EP0278112B1 (es)
JP (2) JPS63169994A (es)
KR (1) KR960010949B1 (es)
CN (1) CN1030999C (es)
AT (1) ATE97421T1 (es)
AU (1) AU592486B2 (es)
DE (1) DE3788216D1 (es)
DK (1) DK3688A (es)
ES (1) ES2059356T3 (es)
FI (1) FI97139C (es)
GB (1) GB2199582A (es)
HU (1) HUT46068A (es)
IL (1) IL85020A (es)
ZA (1) ZA8860B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329693A4 (en) * 1986-10-30 1989-09-26 Synergen Biolog Inc HUMAN PANCREAS SECRETIONAL TRYPSIN INHIBITORS, MANUFACTURED BY DNA RECOMBINATION METHODS AND METHOD FOR THEIR PRODUCTION.
JPS6427473A (en) * 1987-07-23 1989-01-30 Mochida Pharm Co Ltd Human pancreas-secreting trypsin inhibitor and production thereof
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DE58907373D1 (de) * 1988-03-07 1994-05-11 Ciba Geigy Modifizierte Proteine.
US5180667A (en) * 1988-03-07 1993-01-19 Ciba-Geigy Corporation Genes encoding eglin C mutants
JPH07102137B2 (ja) * 1988-07-19 1995-11-08 塩野義製薬株式会社 修飾ヒトｐｓｔｉ
DE3907492A1 (de) * 1989-03-08 1990-09-13 Biotechnolog Forschung Gmbh Verfahren zur isolierung und reinigung von hpsti und hpsti-varianten
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
EP0699750A1 (en) * 1994-06-07 1996-03-06 Gesellschaft für biotechnologische Forschung mbH (GBF) A collection of phagemids, a collection of Escherichia coli cells carrying the phagemids, a collection of phagemid particles produced from said collection and phagemid particles obtained according to the process
US6703201B1 (en) 1995-10-27 2004-03-09 Sagami Chemical Research Center Human PEC-60-like protein and DNA encoding this protein
JPH09124698A (ja) 1995-10-27 1997-05-13 Sagami Chem Res Center ヒトｐｅｃ−６０様蛋白質およびそれをコードするｄｎａ
US5851987A (en) * 1997-04-14 1998-12-22 Incyte Pharmaceuticals, Inc. Human tumor-associated Kazal inhibitor-like polypeptides and encoding polynucleotides
WO2008052238A1 (en) * 2006-11-01 2008-05-08 The University Of Sydney Treatment of urological cancer
EP2109457B1 (en) * 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
JP6685925B2 (ja) 2014-04-17 2020-04-22 シンセティック バイオロジクス，インコーポレイテッド 治療用として改善された特性を有するβ−ラクタマーゼ
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス，インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
KR102467968B1 (ko) 2014-10-08 2022-11-16 신세틱 바이오로직스, 인코퍼레이티드 베타-락타마제 제형 및 이의 용도
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3261662B1 (en) 2015-02-23 2021-07-21 Synthetic Biologics Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
AU2016229976B2 (en) 2015-03-06 2021-11-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2701890C2 (de) * 1977-01-19 1983-08-04 Hoechst Ag, 6230 Frankfurt Peptielischer Glycosidhydrolase-Inhibitor aus einem Streptomyceten und seine Verwendung
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
US4760130A (en) * 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトｐｓｔｉの製造法
CA1339736C (en) * 1986-10-14 1998-03-17 Shionogi & Co., Ltd. Method for preparing fusion proteins
EP0329693A4 (en) * 1986-10-30 1989-09-26 Synergen Biolog Inc HUMAN PANCREAS SECRETIONAL TRYPSIN INHIBITORS, MANUFACTURED BY DNA RECOMBINATION METHODS AND METHOD FOR THEIR PRODUCTION.

Also Published As

Publication number Publication date
DK3688A (da) 1988-07-08
EP0278112A3 (en) 1990-01-10
FI97139C (fi) 1996-10-25
CN88100146A (zh) 1988-08-31
ATE97421T1 (de) 1993-12-15
KR880009125A (ko) 1988-09-14
EP0278112B1 (de) 1993-11-18
ZA8860B (en) 1988-10-26
AU592486B2 (en) 1990-01-11
EP0278112A2 (de) 1988-08-17
US5126322A (en) 1992-06-30
JPS63169994A (ja) 1988-07-13
GB8700204D0 (en) 1987-02-11
DE3788216D1 (de) 1993-12-23
AU1003888A (en) 1988-09-01
FI880017A0 (fi) 1988-01-05
IL85020A (en) 1993-02-21
IL85020A0 (en) 1988-06-30
FI97139B (fi) 1996-07-15
FI880017L (fi) 1988-07-08
GB2199582A (en) 1988-07-13
DK3688D0 (da) 1988-01-06
HUT46068A (en) 1988-09-28
JPH10117786A (ja) 1998-05-12
CN1030999C (zh) 1996-02-14
KR960010949B1 (ko) 1996-08-14

Similar Documents

Publication Publication Date Title
ES2150983T3 (es) Productos proteicos bactericidas estables que incrementan la permeabilidad y composiciones farmaceuticas que los contienen.
ES8601108A1 (es) Procedimiento para la obtencion de eglinas b o c modificadas
ES8605771A1 (es) Procedimiento para preparar un polipeptido
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
ES2046237T3 (es) Acidos boronicos peptidos inhibidores de proteasas de tipo tripsinico.
DK3688A (da) Pankreatisk sekretorisk trypsininhibitor og varianter deraf fremstillet af en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert samt farmaceutisk anvendelse deraf
MX9300492A (es) Soporte inmovilizado de nucleotido y metodo para su produccion.
ES2056817T3 (es) Transformacion de trichoderma.
EP0307592A3 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
ES2062514T5 (es) Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.
ES2052588T3 (es) Celulas de plantas preparadas por ingenieria genetica, que muestran resistencia a los inhibidores de la glutamina sintetasa.
AR035016A1 (es) Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.
AR055179A1 (es) Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
MX9305913A (es) Polipeptidos implicados en la biosintesis de las estreptograminas, secuencias nucleotidicas que las codifican, procedimiento para su produccion y procedimiento para la obtencion de las estreptograminas.
ES2056798T3 (es) Procedimiento para la obtencion de proteinas por tecnologia genetica con utilizacion de celulas hospedantes gram-negativas.
ES2114555T3 (es) Nuevo interferon gamma humano recombinado.
ES2078925T3 (es) Proteinas de la estreptoquinasa, genes correspondientes, recombinantes plasmidicos correspondientes, transformantes correspondientes y procedimientos para su preparacion.
GB8906156D0 (en) Production and use of anthelmintic agents and protective immunogens
DK0674714T3 (da) Rekombinant gastrisk lipase fra hunde og farmaceutiske sammensætninger
PT672124E (pt) Utilizacao de uma sequencia de dna codificadora de uma proteina que degrada acido oxalico como gene de seleccao
DE3852105D1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
AR039021A1 (es) Gen humano de la proteasa desubiquitinante del cromosoma 7 y su ortologo murino
AR018532A1 (es) Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas
ES8707258A1 (es) Procedimiento para preparar derivados de aminoacidos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 278112

Country of ref document: ES